Literature DB >> 22351480

Anorexigenic effects of miglitol in concert with the alterations of gut hormone secretion and gastric emptying in healthy subjects.

H Kaku1, Y Tajiri, K Yamada.   

Abstract

Although the α-glucosidase inhibitor miglitol (MG) has been reported to have anorexigenic effects, the mechanism remains to be elucidated. The objective of this study was to explore the effects of MG on appetite in relation to concomitant changes in postprandial gut hormone levels. This randomized open-label crossover study included 20 healthy volunteers. The effects of 50 mg MG on glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and ghrelin levels were assessed in conjunction with a simultaneous determination of appetite scores using visual analogue scales (VAS) over 3 h after the ingestion of a 592 kcal test cookie. Additionally, the gastric emptying rate (GER) was measured using breath ¹³CO₂ appearance in 10 subjects. 12 subjects were administered 50 mg MG thrice a day for 1 week, and alterations of the gut hormone levels and the VAS scores for appetite were evaluated. MG pre-administration resulted in a significant enhancement of GLP-1 and PYY responses induced by the cookie ingestion. Following MG administration, ghrelin level declined at 1 h, with a persistent suppression during the postprandial phase in contrast to the restoration to the basal level without MG. Furthermore, MG pre-administration suppressed appetite and maintained satiety evaluated using a VAS rating with concomitant inhibition of GER after cookie ingestion. One-week administration of MG did not influence either gut hormone levels before a meal or VAS rating during a whole day. These observations suggest that MG exerts an anorexigenic effects with concomitant alterations of gut hormone secretions and gastric emptying after meal ingestion. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22351480     DOI: 10.1055/s-0032-1304563

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  7 in total

Review 1.  Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis.

Authors:  Se Hee Min; Jeong-Hwa Yoon; Seokyung Hahn; Young Min Cho
Journal:  J Diabetes Investig       Date:  2017-10-25       Impact factor: 4.232

Review 2.  Review: Miglitol has potential as a therapeutic drug against obesity.

Authors:  Satoru Sugimoto; Hisakazu Nakajima; Kitaro Kosaka; Hajime Hosoi
Journal:  Nutr Metab (Lond)       Date:  2015-12-01       Impact factor: 4.169

3.  Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study.

Authors:  Hiroaki Ueno; Wakaba Tsuchimochi; Hong-Wei Wang; Eiichiro Yamashita; Chikako Tsubouchi; Kazuhiro Nagamine; Hideyuki Sakoda; Masamitsu Nakazato
Journal:  Diabetes Ther       Date:  2015-06-09       Impact factor: 2.945

4.  Postprandial effects of a polyphenolic grape extract (PGE) supplement on appetite and food intake: a randomised dose-comparison trial.

Authors:  Hyun-San Shin; Sophie Kindleysides; Wilson Yip; Stephanie C Budgett; John R Ingram; Sally D Poppitt
Journal:  Nutr J       Date:  2015-09-14       Impact factor: 3.271

5.  Appetite and Gut Hormones Response to a Putative α-Glucosidase Inhibitor, Salacia Chinensis, in Overweight/Obese Adults: A Double Blind Randomized Controlled Trial.

Authors:  Lihong Hao; Yvette Schlussel; Krista Fieselmann; Stephen H Schneider; Sue A Shapses
Journal:  Nutrients       Date:  2017-08-12       Impact factor: 5.717

6.  Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.

Authors:  Julio Rosenstock; William T Cefalu; Pablo Lapuerta; Brian Zambrowicz; Ike Ogbaa; Phillip Banks; Arthur Sands
Journal:  Diabetes Care       Date:  2014-09-11       Impact factor: 19.112

7.  Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes.

Authors:  Tsuyoshi Yanagimachi; Yukihiro Fujita; Yasutaka Takeda; Jun Honjo; Hiroki Yokoyama; Masakazu Haneda
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-24       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.